Cargando…

Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis

The optimal treatment regimen for breast cancer patients with gBRCA mutations remains controversial given the availability of numerous options, such as platinum-based agents, polymerase inhibitors (PARPis), and other agents. We included phase II or III RCTs and estimated the HR with 95% CI for OS, P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Wanyi, Wu, Yun, Ma, Fei, Fan, Jinhu, Qiao, Youlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966507/ https://www.ncbi.nlm.nih.gov/pubmed/36836123 http://dx.doi.org/10.3390/jcm12041588

Ejemplares similares

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
por: Pishvaian, Michael J, et al.
Publicado: (2017)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
por: Nogueira Costa, Inês, et al.
Publicado: (2022)

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents
por: Darabi, Sourat, et al.
Publicado: (2022)

Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors
por: Imyanitov, Evgeny, et al.
Publicado: (2021)

Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis
por: Poggio, Francesca, et al.
Publicado: (2018)

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)

Evolution of Pre-Existing versus Acquired Resistance to Platinum Drugs and PARP Inhibitors in BRCA-Associated Cancers
por: Yamamoto, Kimiyo N., et al.
Publicado: (2014)

Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
por: Stossel, Chani, et al.
Publicado: (2023)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance
por: Pandya, Deep, et al.
Publicado: (2021)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis
por: Wang, Ju, et al.
Publicado: (2020)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
por: Dziadkowiec, Karolina N., et al.
Publicado: (2017)

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
por: Petrelli, Annalisa, et al.
Publicado: (2023)

Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer
por: Shao, Nan, et al.
Publicado: (2019)

Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing
por: Wang, Nan, et al.
Publicado: (2020)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy
por: Jacob, Saya L., et al.
Publicado: (2020)

Resistance to PARP Inhibitors After First-Line Platinum-Based Chemotherapy in a Patient with Advanced Ovarian Cancer with a Pathogenic Somatic BRCA1 Mutation
por: Zhong, Lan, et al.
Publicado: (2023)

Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials
por: Purwar, Roli, et al.
Publicado: (2023)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
por: Faraoni, Isabella, et al.
Publicado: (2018)

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
por: Shao, Fengping, et al.
Publicado: (2021)

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
por: Dilmac, Sayra, et al.
Publicado: (2023)

Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review
por: Sun, Ximu, et al.
Publicado: (2021)

TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status
por: Ben Khaled, Najib, et al.
Publicado: (2022)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers
por: Sokol, Ethan S., et al.
Publicado: (2022)

Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
por: Wang, Chuanlin, et al.
Publicado: (2022)

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
por: Nesic, Ksenija, et al.
Publicado: (2023)

Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells
por: Kawanishi, Miki, et al.
Publicado: (2022)

Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells
por: Moustafa, Dina, et al.
Publicado: (2021)

BRCA1 and BRCA2 Gene Mutations and Lung Cancer Risk: A Meta-Analysis
por: Lee, Yen-Chien, et al.
Publicado: (2020)

BRCA1/BRCA2 mutation spectrum analysis in South Asia: a systematic review
por: Kharel, Sanjeev, et al.
Publicado: (2022)

PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology
por: Miglietta, Federica, et al.
Publicado: (2022)

A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer
por: Alameddine, Zakaria, et al.
Publicado: (2023)

Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
por: Hirotsu, Yosuke, et al.
Publicado: (2020)

BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials
por: Li, Shan, et al.
Publicado: (2021)

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
por: Bizzaro, Francesca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hnrvneg8jfqlhn84rg8p0ur3mv